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In recent years, significant advances were made in the determina-
tion of optimal therapeutic dosage regimens for many drugs. Perhaps 
the main thrust in this area has been in the development of sensitive 
assay techniques allowing effective selection of dosage regimens on the 
basis of pharmacokinetic and biopharmaceutic knowledge. This has re-
sulted in more accurate dosage selection with concomitant improvement in 
therapy and decreased incidence of adverse effects.''" Furthermore, the 
availability of serum assays for drugs has made it possible to maintain 
drug concentration in a therapeutic range for longer periods of time 
2 3 
without risking the danger of serious toxicity, ' or subtherapeutic 
4 
effect. This is especially important for those drugs having a narrow 
therapeutic index and a highly variable half-life such as that seen with 
the digitalis glycosides. 
Digitalis glycoside serum assay utilization at its inception was 
low. However, as techniques of measurement improved and became increas-
ingly more available, the frequency with which digitalis glycoside 
assays are ordered has dramatically risen.
1 , 5
 With this increase, much 
confusion has developed concerning assay interpretation resulting in 
severe criticism of the clinical utility of digitalis glycoside as-
5,6,7,8 
says. ' ' ' 
The interpretation of digitalis glycoside serum assays requires an 
9-12 
appreciation of laboratory methodology, interpatient variability in 
2 
19 13 18 
pharmacologic response, as well as the patient's disease state, 
20 
age, sex and body size. Most clinical symptoms of digitalis toxicity 
are nonspecific and should therefore be interpreted accordingly.
 1 , 4 , 2 1 
Laboratory values such as serum potassium, calcium, magnesium, 
oxygen tension and pH also play important roles in the evaluation of 
19 
patient response to digitalis glycosides. Appraisal of patient com-
pliance is necessary for adequate assessment of therapy with digitalis 
22 
glycosides. Numerous drug interactions may have a significant bearing 
on therapeutic success with digitalis glycosides and should therefore be 
19 
considered. In addition, misunderstanding of pharmacokinetic princi-
ples and their application can further complicate the assessment of a 
23 
patient's clinical status. 
hrror in the utilization of assays is more apt to occur when such a 
large variety of factors must be considered. A study with digitalis 
glycoside assays has recently revealed significant deficiencies in the 
area of appropriateness of assay indication and interpretation, and in 
g 
the appropriateness of dosage adjustments following assay reports. 




It was the purpose of the present study to examine some of these 
problems with regard to the use of digitalis glycoside serum assays as 
they occur in a semi-private hospital setting. The study was designed 
to gain additional knowledge in the following areas: a) frequency of 
assay utilization, b) appropriateness of assay indication, cj appropri-
ateness of assay use as measured by blood sampling time, dj actual assay 
levels, e) appropriateness of dosage adjustments, f) patient costs and 
g) physician understanding of digitalis glycoside assay utilization, 
3 
METHODS 
The study was performed over 35 consecutive days in a semi-private 
350 bed hospital located in Salt Lake City, Utah. The hospital was 
staffed by both resident and private physicians. Criteria for 
exclusion of physicians from the study include prior knowledge of the 
study or lack of cooperation in the study. 
Data Collection 
All requests for inpatient digitalis glycoside assays were re-
ceived by Nuclear Medicine technicians who recorded code number, date, 
time received in laboratory, patient name, patient hospital number, 
patient room number, cost to patient and the serum level which was 
determined using the DIGI-TAB Radioimmunoassay Digoxin Diagnostic Kit 
developed by Nuclear Medical Laboratories, Inc., Dallas, Texas. This 
information, with the exception of the actual serum level, was given to 
the investigator who reviewed all patient charts for information affect-
ing assay use and interpretation (Appendix A). All data were collected 
between 12 and 24 hours after the time of the initial request, thus 
allowing physicians sufficient time for recording information. Informed 
written consent was obtained from each patient. 
If electrocardiograms (ECG) were ordered within 48 hours previous 
to the time of the initial assay request, they were photocopied. Other 
baseline ECGs were photocopied as well, if they were found in the chart. 
The ECGs and a copy of the corresponding Patient Data Collection sheet 
were sent to another hospital for independent interpretation by two 
board certified cardiologists. Both cardiologists were blinded to 
patient names, physician names and the hospital name. Each rated all 
patients' ECGs with an overall evaluation of Toxic, Possibly Toxic, 
Probably Non-Toxic and Non-Toxic, corresponding to scores of 4, 3, 2 and 
1 respectively. Each cardiologist worked independently and was unaware 
of interpretations by the other. Inter-rater reliability was measured 
26 
by the Pearson Product-Moment Correlation Formula. 
A theoretical dose was calculated for each patient where possible 
20 
using Jelliffe's equation: 
, . . Creatinine Clearance 
14 + 
Maintenance Dose = (Total Body Stores) 
This dose was then compared to the actual dosage which was received to 
allow for evaluation of the appropriateness of the current regimen 
(Appendix B). 
Creatinine clearance was estimated using the Siersback-Nielson 
27 
nomogram. Serum potassium, oxygen tension and pH values ordered with-
in 48 hours previous to the time of the initial request for serum assays 
were obtained from the chart. The most recent values of serum calcium, 
magnesium, creatinine and blood urea nitrogen were recorded if these 
laboratory values were obtained during each patient's current admission. 
Laboratory values ordered after the time of the original request for 
digitalis glycoside assays were not recorded. 
5 
A complete problem list from each patient chart as well as the in-
dication for digitalis glycoside therapy, current dosage regimen, most 
recent dosage change and the exact time of the most recent dose re-
ceived prior to serum sampling were obtained when available. All med-
ications received in the hospital and medications taken at home within 
three months prior to admission were recorded as obtained from the pat-
ient's chart. 
Evidence of toxicity was obtained from the chart in three cate-
gories: 1) Gastrointestinal symptoms, 2) Central nervous symptoms, and 
3) Visual symptoms (Appendix A). 
Evidence of subtherapeutic effect was obtained as recorded in the 
patient's chart in two categories: 1) Symptoms of disease state deter-
ioration, and 2)  Compliance history (Appendix A). Compliance was re-
corded as being excellent, good, fair or poor corresponding to the num-
ber of doses missed per month equal to: a) one or less, b) two, c)three 
or d) greater than three, respectively. Poor compliance histories re-
ceived Clinical Evaluation Point System scores of minus one as discussed 
below (Appendix B). Adjustments made in therapy following the appear-
ance of assay results in the chart were noted on the Patient Data Col-
lection Sheet. Digitalis glycoside therapy was recorded as increased, 
decreased or not changed. 
At the end of the five weeks, each physician was interviewed by 
telephone using a questionnaire (Appendix c). The investigator used an 
identical explanation when discussing its purpose with all physicians 
interviewed (Appendix D). Physicians were not permitted to discuss the 
questions with the investigator. Only the re-reading of questions to 
the physicians was allowed. 
6 
Evaluation 
The frequency of availability of each piece of information that 
may be used for clinical evaluation of patients was determined,, Each 
assay was assigned a score according to a standardized clinical eval-
uation system,(Appendix B). A score of 10 or more was interpreted as 
a reasonable indication for the assay on the grounds of suspected tox-
icity. A score of -10 or less was interpreted as a reasonable indica-
tion for the assay on the grounds of suspected subtherapeutic effect. 
A score from minus nine to nine was interpreted as an unreasonable indi-
cation for the assay due to a high likelihood that the serum level would 
be within the therapeutic range and would probably not benefit the 
patient in the form of indicated alterations in therapy. The scores 
were recorded and compared to actual serum level reports. The relia-
bility of this method in predicting assay results was then assessed. 
The actual adjustment in therapy ordered following assay results 
was compared to: a) therapy which patients would have received following 
ideal clinical assessment alone, and b) therapy which patients would have 
received under ideal clinical assessment with assay results. 
Therapy which patients would have received following ideal clinical 
assessment alone is defined as that therapy required for correction of 
the clinical evaluation score to within normal limits (WNL). In other 
words, if the patient scored in the toxic range, the dosage shoud be 
decreased; if the patient scored in the subtherapeutic range, the dosage 
should be increased; and, if the patient scored within normal limits, 
the dosage should not be changed. 
The therapy which patients would have received following ideal 
clinical assessment with assay results was determined on the basis of 
clinical and laboratory information (Appendix E). 
7 
A patient cost analysis was then performed based on the current 
rates. Annual estimations of patient losses were made on the basis of 
this five week period. 
Finally, the physicians' quiz was scored (Appendix C). 
8 
RESULTS 
Uver a period of 35 days, 29 physicians requested 107 digoxin and 
four digitoxin assays for 70 inpatients. One patient had a total of 20 
assays performed during the period of this study. Of the 111 total 
assays performed, 27 physicians, 101 assays and 68 patients qualified 
for entry into this study. Ten physicians were residents. The remain-
ing 17 were in private practice. Resident signatures appeared on 70 
assay requests while 31 requests were signed by physicians in private 
practice. The range of patient ages was from 35 to 90 years. Ninety 
percent of all patients were at least 60 years of age. 
Data were available for 10 of 11 factors that may be used for clin-
ical evaluation of digitalis toxicity. The frequency of availability of 
this information in patient charts is shown in Table I. 
TABLE I: Frequency of Available Information in Patient Charts 
Frequency of Availability 
Problem List 94% 
Medication History 89% 
Potassium 88% 
Indication for Digitalis Glycosides 84% 
Regimen Prior to Admission 82% 
Serum Creatinine/Blood Urea Nitrogen 79% 





Fifty-two patients had electrocardiograms available at the time 
of assay request, and all were rated by the two cardiologists. Reli-
ability of their ratings was 0,78 as assessed by the Pearson Product-
26 
Moment Correlation Formula and is considered to be adequate by this 
method. The ratings by each cardiologist are shown in Table II. 
TABLE II: Electrocardiogram Rating Summary by Two Cardiologists 
Possibly Toxic Toxic Uther 
Cardiologist A 11 0 41 
Cardiologist B 11 2 39 
In tne clinical evaluation of assay necessity (Table 111), 45 
assays (.44.5 percent) scored from minus nine to nine points and were 
deemed unnecessary assays, or within normal limits (WNL). Twenty-two 
of these (50 percent) had scores of zero. A total of 56 assays (55.4 
percent) were deemed necessary by the scoring system. Forty-six assays 
received clinical evaluation scores of 10 or more for a toxic rating, 
Ten assays received clinical evaluation scores of -10 or less for a 
subtherapeutic rating. It should be noted that patient number six had 
a total of 20 assays performed. Of these, 13 assays scored in the toxic 
range by the Clinical Evaluation System, However, 10 of the 13 assays 
were ordered on a daily basis and were therefore unable to give any 
beneficial or needed information that could alter the patient's overall 
therapy. Consequently, a more accurate estimation of necessary assays 
would be 45.5 percent. 
Thirteen assays were obtained less than six hours after the pre-
23 
vious dosage, thus not allowing proper distribution to take place. 
23 
Although Jisalo recommends an eight hour minimum, two additional 
samples were obtained less than eight hours after the previous dosage. 
One physician requested a specific time for serum sampling for a single 
assay. 
TABLE III: Results of Clinical Evaluation System 
for Assay Necessity 







A total of 22 assays was reported greater than or equal to 2.2 
ng/ml for digoxin. Eight assays for digoxin were reported greater than 
or equal to 3.0 ng/ml. None of the four digitoxin assays reported in 
this study was in the toxic range. Non-toxic ranges by our laboratory 
methods are regarded as below 2.2 ng/ml for digoxin and below 45 ng/ml 
for digitoxin. 
Assay results are compared to clinical evaluation scores in Table 
IV. The utility of the Clinical Evaluation Score is presented in 
Figure 1. Ninety-eight percent of digoxin assay reports were predict-
ably in the therapeutic range of 0.5 to 2.1 ng/ml. Toxic and subther-
apeutic concentration ranges were not predictable by this method, 
TABLE IV: Clinical Evaluation in Comparison with 






















*See Appendix D for Clinical Evaluation Scoring System 
tWithin Normal Limits 
ll 
FIGURE 1: Predictability of Assay Reports Using a 
Clinical Evaluation Scoring System 
Assay Ranges 
Evaluation of the appropriateness of therapy is reported in two 
categories: 1) Adjustments in therapy following all assays (Table V), 
and 2) Unwarranted adjustments in therapy (Table VI). Both categories 
are divided into unnecessary and necessary assays, corresponding to 
clinical evaluation scores of minus nine to nine, or less than or equal 
to -10, or greater than or equal to 10, respectively. Tables V and VI 
are further subdivided into: a) actual adjustment in therapy that 
patients received, b) clinical adjustment in therapy that patients 
would have received had there been no digitalis glycoside assays avail-
able, and c) ideal adjustment in therapy that patients should have re-
ceived based on proper interpretation of both clinical presentation and 
serum assay results. 
Table V lists the total numbers of adjustments in dosage for each 
of the three methods used for patient assessment. However, disparity 
between the methods can be seen on closer evaluation of either the total 
12 
numbers of warranted adjustments or the total numbers of unwarranted 
adjustments that were made in therapy when compared to ideal adjustments. 
Table VI lists unwarranted adjustments in therapy as compared to ideal 
adjustments in therapy. 
TABLE V: Adjustments in Therapy Following All Assays 
A. Unnecessary Assays: 55 total 
Method Used for Increases Decreases No Adjustments 
Patient Assessment in Dosage in Dosage in Dosage 
Actual 4 2 49 
Clinical Only 1 U 54 
ideal 1 0 54 
B. Necessary Assays: 46 total 
Method Used for Increases Decreases No Adjustments 
Patient Assessment in Dosage in Dosage in Dosage 
Actual 9 6 31 
Clinical Only 12 33 1 
Ideal 12 18 16 
TABLE VI: Unwarranted Adjustments in Therapy 
Unnecessary Assays: 55 total 
Method Used for Increases Decreases No Adjustments 
Patient Assessment in Dosage in Dosage in Dosage Totals 
Actual 2 2 0 4 
Clinical Only 0 0 0 0 
B. Necessary Assays: 46 total 
Method Used for Increases Decreases No Adjustments 
Patient Assessment in Dosage in Dosage in Dosage Totals. 
Actual 3 1 16 20 
Clinical Only 3 15 0 18 
Of the 55 unnecessary assays obtained, four (7.3 percent) resulted 
in unwarranted adjustments in dosage. There were no unwarranted adjust-
ments recommended with the use of clinical criteria alone. Or the 46 
13 
necessary assays obtained, 20 (43 percent) resulted in unwarranted ad-
justments in dosage. This compared with 18 C39 percent) unwarranted 
adjustments with the use of clinical criteria alone. 
The number of assays performed on each patient varied (Table VII). 
Consequently, costs per patient ranged from as little as $17.50 to as 
much as $560.00 for digitalis glycoside assay service alone. A patient 
cost analysis appears in Table VIII. 
TABLE VII: Frequency of Assay Performance 
on Individual Patients 
Number of Assays Number of Patients Percent 
Performed on Receiving this Number of Total 
Each Patient of Assays Patients 
1 S4 79% 
2 12 18% 
3 1 1.5% 
20 1 1.5% 
TABLE VIII: Patient Cost Analysis* Based on 
Frequency Occuring in this Five Week Period 
Cost per Categories Projected Annual 
Assay Charge Category Category per year Patient Costs 
Standard Digoxin $25.75 1084.6 $27,928.45 
Standard Digitoxin 30.99 41.7 1,251.00 
Stat Digoxin/Digitoxin 44.10 41.7 1,838.97 
Late Stat Digoxin/Digitoxin 10.00 62.6 626.00 
TOTAL , = $31,644.42 
*Based on current hospital rates in effect by the end of this 
study. 
Annual patient losses may approximate $17,250 as calculated by the 
equation: 
Losses = (% Unnecessary Assays) (Annual Patient Costs) 
14 
A summary of selected physician quiz results appears in Table IX. 
Quiz performance was approximately the same for both groups of physi-
cians and could not be correlated to rationale in ordering assays or to 
frequency of use. 
TABLE IX: Summary of Physician Quiz Results for Selected Questions* 
Resident M.D, Private M.D. All Physicians 
Question Scores Scores Scores 
Number Question Content (10 quizzes) (12 quizzes) (22 quizzes) 
4 Digoxin half-life 35% 4% 18% 
5 Digoxin serum 
sampling time 20% 67% 46% 
7 Digoxin assay 
costs to patient 20% 42% 32% 
10 Objective dosing 
techniques 0% 0% 0% 
*See Appendix B for full questions and scoring system. Appendix 
F is a comprehensive summary of results. 
Although the knowledge and understanding of half-life information 





 only 18 percent of all physicians in this study ap-
peared to be knowledgeable in this area. Thirty-five percent of resi-
dents responded correctly while less than four percent of physicians in 
private practice could answer this question. 
Physicians in private practice appeared to be more aware of the 
proper timing necessary for ordering digoxin assays. This was seen by 
their performance both on the quiz and in clinical results. Physicians 
in private practice scored a mean of 67 percent on this question (num-
ber five in Table IX) versus mean resident scores of 20 percent. Fifty 
percent of the resident physicians requested 77 percent of assays that 
were ordered less than six hours after previous dosages, whereas only 
15 
lb percent of the private physicians ordered 23 percent of assays, before 
the six hour limit. However, it should be borne in mind that signatures 
of residents do not necessarily reflect their own decisions. 
Nearly 70 percent of all physicians interviewed had no idea what 
assay costs were to the patient. Eighty percent of residents and 58 
percent of the private physicians were unaware of the costs involved. 
Also noteworthy is the fact that none of the 23 physicians inter-
viewed used an objective technique for dosage determination. All of 
them determined dosages from clinical judgment despite the fact that 
28 
there now exist several more objective methods for doing so. 
16 
DISCUSSION 
The frequency of assay utilization in this hospital seemed to be 
approximately twice that which was necessary. Based on criteria util-
ized in this study, over half of all digitalis glycoside serum assays 
requested were not indicated. The reliability of these criteria was 
demonstrated by other findings: a) none of the assays receiving a clin-
ical evaluation score of less than 10 were reported above 2.1 ng/ml 
(Figure 2). This is not surprising since the criteria was purposely 
weighted to support any suspicion of toxicity, b) none of the assays 
receiving a clinical evaluation score of less than 10 resulted in dos-
age adjustment recommendations that differed from an accepted theoreti-
cal method using assay results. Reliability is further supported by the 
26 
close agreement with the findings of Slaughter et al. wh.o reported 
that 49 percent of 145 cases had inappropriate indications for the use 
26 
of serum assays. Slaughter et al. also reported that 86 percent of 
assays were performed at steady state making 14 percent of their assay 
23 
results uninterpretable on this, basis according to Jisalo. Steady 
state was not evaluated in this study. 
Measurement of assays before the recommended time interval is simi-
lar in both studies. Slaughter et al. showed that seven percent of assays 
were obtained before a six hour interval versus 13 percent observed in 
the present study. Closer examination, however, reveals a much larger 
deficiency in this area. Most assay requests in the present study were 
written "digoxin level," "digoxin level tomorrow" or "digoxin level 
e 
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today." Only one physician specified a particular time interval and in 
this case, it was for only one patient. In addition, quiz results show 
that only 20 percent of the residents, who were responsible for 70 
percent of the assays ordered, knew when a digoxin level reached the 
beta phase of elimination and therefore became the earliest time that a 
23 
serum sample could be drawn to obtain meaningful assay results. This 
suggests that the 13 and 7 percent error rates are actually underestim-
ations of an error rate which would have occurred without the "protection" 
afforded by the combined systems of the laboratory blood drawing team 
and the medication administration system of the nursing staff. The 
blood drawing team routinely collects samples before the administration 
of all early morning medications, unless specifically ordered otherwise. 
Nursing staff concurrently administers all "once daily" medications at 
9 a.m. Consequently, there is a tendency for the large majority of 
digoxin serum samples to be obtained at trough levels just prior to the 
next dose. Data results may thus be mistakenly interpreted as an area 
of expertise when in fact such results may be due to a predetermined 
protocol. 
Of the assays that were indicated in this study, 43 percent were 
followed by inappropriate adjustments in therapy. The reasons for which 
ideal adjustments in therapy differed from that which patients actually 
received appear in Table X. The overall number of inappropriate adjust-
ments that patients would have received with proper clinical assessment 
without the aid of digoxin assay information (39 percent) does not appear 
to be different from what they actually received when the assay was 
available. This suggests that the assay may have actually contributed 
to confusion regarding assay interpretation and ultimate patient therapy. 
19 
Slaughter et al. reported 36 percent inappropriate adjustments by their 
criteria but made no additional comparisons with recommendations made 
on the basis of clinical assessment only. The 43 percent reported in 
the present study include only those adjustments that were or were not 
made within 12 to 24 hours after the initial order as methods indicated. 
This time limit may account for the higher incidence of inappropriate 
adjustments observed in this study when compared to the results of 
Slaughter's group who followed their patients for 48 hours. 
TABLE X: Explanation For Differences Between Ideal Adjustment 







Patients Explanation for Adjustment Recommendation 
Increase 6 CES* subtherapeutic (< -10], assay maximum 
1.1 ng/ml. Patients needed increase or re-
start of previous dosage. 
Decrease 6 CES* toxic U 10), assay minimum 2.2 ng/ml. 
Trial decrease in dosage is indicated. 
6 CES* toxic (18-20), assay 1.7-2.1 ng/ml. 
Trial decrease in dosage is indicated. 
No change 5 CES* WNL+ C-9-+9), assay 0.5-2.1 ng/ml. 
Patients had no clinical problems and 
required no change. 
1 CES* 18, assay 0.8.ng/ml. Toxicity rare 
at this level. 
*CES = Clinical Evaluation System score 
tWNL = Within Normal Limits. 
Errors made in assay utilization, assay interpretation and therapy 
outcome are ultimately passed on to patients in terms of costs, discomfort 
and length of hospital stay. This is clearly demonstrated by a case 
20 
in the present investigation. A 72 year old female with severe chest 
pain was admitted in order to rule out myocardial infarction. Iatro-
genic digitalis toxicity in the form of ventricular fibrillation, severe 
hallucinations, confusion, stupor, fatigue, nausea and vomiting marked 
this patient's complicated hospital course. During the course of the 
present study, 20 digoxin assays were obtained, costing the patient 
nearly $600.00 for digitalis glycoside assay service alone. Three of 
these assays were obtained less than six hours after the previous dose 
and were therefore uninterpretable. Seventeen of the assays were unnec-
essary. Seven scored in the non-toxic range, while the other 10 were 
obtained on a daily basis and therefore added nothing to the knowledge 
of the patient's status or to the benefit of the patient in terms of 
therapy that she may not have otherwise received. 
The knowledge of half-life and the understanding of its use are 
basic concepts necessary for proper clinical assessment and therapy. 
Results of the physician quiz and clinical performance suggest that 
clinicians are generally not aware of the importance of pharmacokinetics 
and the impact that this may have on clinical assessment and outcome of 
patient therapy. 
The use of objective methods for dosing digitalis glycosides has 
30 31 
been shown to effectively decrease the incidence of adverse effects. ' 
In light of this, the use of clinical judgment as the basis for dosage 
adjustment of digitalis glycosides, such as that seen with all of the 
physicians in this study may be inappropriate. It should be noted, how-
ever, that not all physicians ordering digitalis glycosides in this hos-
pital, but only those ordering blood levels, were included in this study. 
21 
In conclusion, it would seem that under the conditions of the 
present study, the following were shown: a) digitalis glycoside serum 
assays were overused which may well reflect overuse on a wider scale; 
b) a large number of digitalis glycoside serum assays obtained was not 
indicated and a greater reliance on clinical parameters may be necessary 
when evaluating patients on digitalis glycosides; c) recognition of the 
importance and implications of proper timing for serum sampling is 
lacking and may result in misinterpretation of assay results; d) a large 
percentage of indicated assays are followed by inappropriate dosage ad-
justments; e) patient costs were unnecessarily high during this period 
and may be twice those which are actual ly necessary on an annual basis 
in this hospital; and f) physician knowledge and understanding of digi-
talis glycoside assay utilization appears to be deficient and may be 
related to suboptimal results observed in this study. 
Physician education and pharmacokinetic consultative services may 
be an answer to this problem. Impact of such consultative services has 
been studied and appears to be effective in improving overall patient 
29 






Patient Data Collection 
PATIENT INFORMATION: 








LAB DATA (within 24 hours unless otherwise specified): 
Potassium: Calcium: 
pH: Serum creatinine/BUN: 
pO 2' Magnesium: 
Problem List: In Chart 
Digoxin Indication: 
Current Digoxin Regimen: 
Most Recent Dose: 
Most Recent Dose Change: 
Current Medications: In Chart 
Past Medication History: 
Not in Chart (listed for cardiologists) 
Not in Chart (listed for cardiologists) 
In Chart Not in Chart 
EVIDENCE FOR TOXICITY: 
Gastrointestinal Symptoms: 























Dyspnea on Exertion 
Arrhythmia Return 
Compliance History: 
Excellent Good Fair Poor 
Edema 
Urinary Frequency 




Clinical Evaluation Point System 
RULE: Clinically Toxic equal 10 points minimum. 
Clinically Subtherapeutic equal -10 points maximum. 
POINTS EVIDENCE 
10 Overdose (acute). Must be documented or highly suspected. 
10 ECG. Must have at least one rating of three or four by at 
least one cardiologist. 
10 Gastrointestinal. Must have at least four symptoms. 
10 Central Nervous System. Must have at least four symptoms. 
10 Visual. 
10 Serum creatinine doubled over any period of time since most 
recent dosage change. 
10 Creatinine Clearance. Must show change of at least 50 percent 
since most recent dosage change (-10 points if such change 
favors improved elimination). 
10 Switching from digitoxin to digoxin. 
-10 Symptoms of regression. Must have more than one symptom. 
9 Gastrointestinal. Must have less than four symptoms, 
9 Central Nervous System. Must have less than four symptoms. 
-9 Symptoms of regression. One symptom 
Potassium. Must be less than or equal to 3.0 
Calcium. Must be greater than or equal to 10.2 
pH. Must be greater than or equal to 7.5 
Magnesium. Must be less than or equal to 1.9. 
p0 2. Must be less than 60.0 without history of chronically 
low p0 2.* 
No other possible underlying disease to explain symptoms. 
Creatinine greater than 2.0 and age greater than 70. 
Theoretical Dose = Present dose - (0.1 mg. or more) 
Theoretical Dose = Present dose + (0.9 mg. or more). 
Compliance. Poor only. (Missing greater than three doses per 
month). 




1. What method of Assay is used for digitalis determination of serum 
levels in this hospital? 
(Ans. Radioimmunoassay (RIA) - one point) 
2. What is the normal therapeutic range for digoxin? 
(Ans. 0.7 ng/ml to 2.0 ng/ml - one point. Accepted 0.5 to 2.2 
ng/ml) 
3. What is generally thought to be a toxic level? 
(Ans. Greater than 2.2 ng/ml depending on disease state being 
treated - one point. Accepted greater than 2.0 ng/ml OR depends 
on disease being treated.) 
4. What is the half-life range for digoxin? What is the mean half-
life? 
(Ans. 24 to 48 hours range, 36 hours mean - one point. Accepted 
1-3 days range - % point, 30-40 hours mean - % point.) 
5. When is the earliest time after an oral dose that a digoxin level 
may be drawn to obtain meaningful results? 
(Ans. after 8 hours - one point. Accepted after 6 hours,) 
6. When are digoxin and digitoxin levels indicated? 
(Ans. Clinical suspicion of toxicity or non-compliance, history 
of unstable renal condition - one point. Accepted any single 
indication - % point, any 2 indications - one point.) 
7. How much do digoxin and digitoxin serum levels cost in this hospital? 
Are there holiday rates? 
(Ans. Digoxin $17.50 normal, $27.50 holiday/off-hours - one point. 
Accepted $15-30.) 
8. What are the most common symptoms of digitalis toxicity? 
(Ans. Gastrointestinal, cardiac and central nervous system -
one point. Accepted any 2 - h point, all 3 - one point.) 
9. What other lab data do you need when evaluating toxicity of digi-
talis glycosides? 
(Ans. EKG, serum creatinine/blood urea nitrogen, potassium, cal-
cium, p02 - one point. Accepted any 2 - h point, more than 2 -
one point.) 
10. What method do you use for calculating a maintenance dose for your 
patients? 
(Ans. Any nomogram or mathematical method - one point.) 
APPEiNDIX D 
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PHYSICIAN TELEPHONE QUIZ EXPLANATION 
Hello, Dr. . This is Jack Wilson. I'm a Doctor 
of Pharmacy Candidate from the University of Utah, and I am currently 
working with the laboratory here at Holy Cross on a project designed 
to improve the dissemination of information with regard to pharmaco-
kinetic interpretation and the utilization of the many drug serum levels 
that are being done in this hospital. 
What I would like to do is ask you a few questions concerning one 
of the drugs for which serum levels are commonly ordered. This will 
appear as an entirely anonymous report and it should take only a few 
moments. 
Would you be willing to help us out? 
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1/R - 1 1 - - '-i - 1 1 - 45 
2/P - 1 1 - 1 1 - 1 - - 50 
3/P NOT INTERVIB l/EI) -
4/R 1 1 1 1 - •s 1 h 1 - 70 
5/R - - 1 - - 1 - h h - 30 
6/R 1 1 1 ht -
!
i - h l - 55 
7/P - 1 1 - - - - 1 - - 30 
8/R 1 1 1 - - h - 1 'i - 50 
9/R - 1 1 - 1 i - 1. 'a h - 50 
10/R 1 1 1 H - h - 'i - - 45 
11/R - 1 1 - 1 h - 1 l - 55 
12/R - 1 1 'i - 's - - l - 40 
13/R 1 1 1 l - h 1 1 l - 75 
14/P - 1 1 1 l 1 's 1 - 70 
15/P 1 1 1 - 1 l 1 's - 70 
16/P - 1 1 - - 'i - h - - 30 
17/P NOT [NTERV1E KED -
18/P - 1 1 - 1 l - 1 h - 55 
19/P 1 1 1 - 1 l - 'i l - 65 
20/P - 1 1 - 1 l 1 l - - 60 
21/P - 1 1 - 1 'i 1 l i - 60 
22/P - 1 1 - - - - h l - 35 
23/P 1 1 1 - 1 1 1 1 l - 80 
24/P NOT INTHRVIE <ED -
25/P - h 1 - - 's - l i - 40 
26/P 7 7 1 ? UNCO -OPERATI L'E 0 
2 7/P NOT INTERVIE VEO -
8/23 20.5/23 22/23 4/23 10/22 14.5/22 7/22 16/22 14/22 0/23 
Residents 50 90 100 35 20 60 20 65 75 0 51.5 
Private 23 88 92 4 67 71 42 79 54 0 49.6 
MEAN SCORES 40 89 96 17 45 66 32 73 64 0 50.4 
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